Akamai Technologies and P3M Works have announced a strategic partnership to deliver zero trust identity, credential, and ...

The Company's proprietary technology utilizing ICAM-1/LFA-1 interaction can potentially address all critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion ...

Collaboration to leverage Akamai's proven Tactical ICAM capabilities and P3M Works ... the unvarnished thinking of our people and exacting analysis of our research processes.